<DOC>
	<DOCNO>NCT02508441</DOCNO>
	<brief_summary>This first-in-human , open-label , dose escalation expansion , 2-part study determine safety , tolerability , maximum tolerate dose Andes-1537 Injection patient advance unresectable solid tumor refractory standard therapy standard therapy available .</brief_summary>
	<brief_title>Phase 1 Safety Tolerability Study Andes-1537 Injection Patients With Advanced Unresectable Solid Tumors</brief_title>
	<detailed_description>Part 1 dose-escalation study establish maximum tolerate dose base dose-limiting toxicity evaluate safety tolerability multiple dose Andes-1537 Injection patient advance unresectable solid tumor refractory standard therapy standard therapy available . Part 2 open-label , dose-expansion study determine safety , tolerability , preliminary efficacy Andes-1537 patient advance solid tumor . In part 2 , patient enrol receive recommend phase 2 dose establish part 1 base safety , tolerability , pharmacokinetics , preliminary efficacy data .</detailed_description>
	<criteria>Men woman 18 year age old Can understand voluntarily sign informed consent form prior studyrelated assessment procedure , able adhere study visit schedule protocol requirement Patient document pathological evidence cancer develop advanced unresectable solid tumor , opinion treat physician , refractory standard therapy standard therapy available Consent tumor biopsy accessible tissue ( optional part 1 , mandatory part 2 ) Part 2 : measureable disease RECIST Have Eastern Cooperative Oncology Group ( ECOG ) performance status ≤ 1 Have adequate organ function , confirm follow laboratory value obtain ≤ 3 day prior first treatment : absolute neutrophil count ≥ 1.5 × 10^9/L ; hemoglobin ≥ 9 g/dL ; platelet ≥ 100 × 10^9/L ; aspartate transaminase alanine transaminase ≤ 2.5 × upper limit normal ( ULN ) ; serum total bilirubin ≤ 2.0 × ULN ; serum creatinine ≤ 1.5 × ULN , estimate measure creatinine clearance ≥ 60 mL/min ; prothrombin time , activate partial thromboplastin time ≤ 1.5 × ULN anticoagulation therapy Female patient childbearing potential must negative serum pregnancy test use adequate contraception prior study entry must agree use adequate contraception study entry least 6 month discontinuation study drug . Male patient screen must agree practice adequate contraception study entry least 6 month discontinuation study drug . Have symptomatic central nervous system metastasis . Patients brain metastases previously treat stable ≥ 4 week treat gamma knife surgery stable ≥ 2 week allow enter study . Have unstable angina , clinically significant cardiac arrhythmia , New York Heart Association Class 3 4 congestive heart failure , prolong QT interval correct wave great 470 m . Receiving treatment medication know produce QT prolongation within 7 day study entry Have prior systemic chemotherapy treatment investigational modality ≤ 5 halflives 4 week , whichever short , prior start treatment Andes1537 recover side effect , grade 2 great , therapy ( except alopecia ) Have major surgery ≤ 2 week prior start treatment Andes1537 recover side effect surgery Are pregnant breastfeed Have DVT venous thromboembolism within 6 week study entry Have active uncontrolled bleeding know bleed disorder Have serious unstable concomitant systemic condition incompatible clinical study , include limited substance abuse , psychiatric disturbance , uncontrolled intercurrent illness ( include active infection ) , arterial thrombosis , symptomatic pulmonary embolism Have know sensitivity component Andes1537 Are unable unwilling follow protocol instruction requirement</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Neoplasms</keyword>
	<keyword>Solid Tumors</keyword>
	<keyword>Advanced Malignancy</keyword>
	<keyword>Cancer</keyword>
</DOC>